01
Cash & equivalents decreased 38.0%
Cash & equivalents changed -38.0% from the comparable as-filed period.
$16.8M→$10.4MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTLISATA THERAPEUTICS, INC.'s latest supported as-filed period reports revenue of $0, 100.0% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -38.0% from the comparable as-filed period.
Net income changed +37.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +18.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LSTA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000320017-26-000038SEC ↗8-KAug 4, 2026Period Aug 3, 20260001140361-26-031028SEC ↗8-KJul 24, 2026Period Jul 24, 20260001140361-26-029541SEC ↗8-KJul 17, 2026Period Jul 16, 20260001140361-26-028763SEC ↗8-KJun 9, 2026Period Jun 8, 20260001140361-26-024560SEC ↗8-KJun 1, 2026Period Jun 1, 20260001140361-26-023397SEC ↗8-KMay 29, 2026Period May 29, 20260001140361-26-023336SEC ↗10-QTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jan 9, 2026Filed Jan 13, 2026 | Mazzo David JPresident & CEO | Grant Or AwardDirect | 81,000 | $0 | $0 | Form 4 ↗ |
| Jan 9, 2026Filed Jan 13, 2026 | Mazzo David JPresident & CEO | Tax WithholdingDirect | 10,503 | $2 | $20,691 | Form 4 ↗ |
| Jan 9, 2026Filed Jan 13, 2026 | Mazzo David JPresident & CEO | Tax WithholdingDirect | 10,515 | $2 | $20,715 | Form 4 ↗ |
| Jan 9, 2026Filed Jan 13, 2026 | Mazzo David JPresident & CEO | Tax WithholdingDirect | 12,224 | $2 | $24,081 | Form 4 ↗ |
| Jan 9, 2026Filed Jan 13, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Revenue changed -100.0% from the comparable as-filed period.
Stock-based compensation changed -10.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000320017-26-000032| Mazzo David JPresident & CEO |
| Tax WithholdingDirect |
| 7,854 |
| $2 |
| $15,472 |
| Form 4 ↗ |
| Jan 9, 2026Filed Jan 13, 2026 | Mazzo David JPresident & CEO | Grant Or AwardDirect | 40,000 | $0 | $0 | Form 4 ↗ |